Citi analyst Geoff Meacham raised the firm’s price target on Gilead (GILD) to $135 from $125 and keeps a Buy rating on the shares. Citi’s survey of 100 physicians indicates strong initial trends for the Yeztugo launch in HIV, the analyst tells investors in a research note. The firm upped sales forecasts and the price target as a result.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strategic Positioning and Extended Patent Protection Justify Buy Rating
- Wells says Biktarvy patent settlement ‘big deal’ for Gilead at, $6-$12 upside
- Gilead Sciences Settles Patent Litigation on Biktarvy
- Gilead settles patent litigations with Biktarvy ANDA filerers
- Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating